144 related articles for article (PubMed ID: 35411762)
1. Investigation of the relationship between serum sclerostin and dickkopf-1 protein levels with bone turnover in children and adolescents with type-1 diabetes mellitus.
Kurban S; Selver Eklioglu B; Selver MB
J Pediatr Endocrinol Metab; 2022 May; 35(5):673-679. PubMed ID: 35411762
[TBL] [Abstract][Full Text] [Related]
2. Increased levels of Dickkopf-1 are indicative of Wnt/β-catenin downregulation and lower osteoblast signaling in children and adolescents with type 1 diabetes mellitus, contributing to lower bone mineral density.
Tsentidis C; Gourgiotis D; Kossiva L; Marmarinos A; Doulgeraki A; Karavanaki K
Osteoporos Int; 2017 Mar; 28(3):945-953. PubMed ID: 27766367
[TBL] [Abstract][Full Text] [Related]
3. High Sclerostin and Dickkopf-1 (DKK-1) Serum Levels in Children and Adolescents With Type 1 Diabetes Mellitus.
Faienza MF; Ventura A; Delvecchio M; Fusillo A; Piacente L; Aceto G; Colaianni G; Colucci S; Cavallo L; Grano M; Brunetti G
J Clin Endocrinol Metab; 2017 Apr; 102(4):1174-1181. PubMed ID: 28388723
[TBL] [Abstract][Full Text] [Related]
4. Serum levels of the bone turnover markers dickkopf-1, sclerostin, osteoprotegerin, osteopontin, osteocalcin and 25-hydroxyvitamin D in Swedish geriatric patients aged 75 years or older with a fresh hip fracture and in healthy controls.
Wanby P; Nobin R; Von SP; Brudin L; Carlsson M
J Endocrinol Invest; 2016 Aug; 39(8):855-63. PubMed ID: 26850415
[TBL] [Abstract][Full Text] [Related]
5. Role of Wnt-signaling inhibitors DKK-1 and sclerostin in bone fragility associated with Turner syndrome.
Chiarito M; Piacente L; Chaoul N; Pontrelli P; D'Amato G; Grandone A; Russo G; Street ME; Wasniewska MG; Brunetti G; Faienza MF
J Endocrinol Invest; 2022 Jun; 45(6):1255-1263. PubMed ID: 35237949
[TBL] [Abstract][Full Text] [Related]
6. Effect of glucocorticoid treatment on Wnt signalling antagonists (sclerostin and Dkk-1) and their relationship with bone turnover.
Gifre L; Ruiz-Gaspà S; Monegal A; Nomdedeu B; Filella X; Guañabens N; Peris P
Bone; 2013 Nov; 57(1):272-6. PubMed ID: 23981659
[TBL] [Abstract][Full Text] [Related]
7. Sclerostin distribution in children and adolescents with type 1 diabetes mellitus and correlation with bone metabolism and bone mineral density.
Tsentidis C; Gourgiotis D; Kossiva L; Marmarinos A; Doulgeraki A; Karavanaki K
Pediatr Diabetes; 2016 Jun; 17(4):289-99. PubMed ID: 26094958
[TBL] [Abstract][Full Text] [Related]
8. Circulating levels of dickkopf-1, osteoprotegerin and sclerostin are higher in old compared with young men and women and positively associated with whole-body bone mineral density in older adults.
Coulson J; Bagley L; Barnouin Y; Bradburn S; Butler-Browne G; Gapeyeva H; Hogrel JY; Maden-Wilkinson T; Maier AB; Meskers C; Murgatroyd C; Narici M; Pääsuke M; Sassano L; Sipilä S; Al-Shanti N; Stenroth L; Jones DA; McPhee JS
Osteoporos Int; 2017 Sep; 28(9):2683-2689. PubMed ID: 28585053
[TBL] [Abstract][Full Text] [Related]
9. Factors associated with serum soluble inhibitors of Wnt-β-catenin signaling (sclerostin and dickkopf-1) in patients undergoing peritoneal dialysis.
Yamada S; Tsuruya K; Tokumoto M; Yoshida H; Ooboshi H; Kitazono T
Nephrology (Carlton); 2015 Sep; 20(9):639-45. PubMed ID: 25974190
[TBL] [Abstract][Full Text] [Related]
10. Effect of aromatase inhibition on serum levels of sclerostin and dickkopf-1, bone turnover markers and bone mineral density in women with breast cancer.
Kyvernitakis I; Rachner TD; Urbschat A; Hars O; Hofbauer LC; Hadji P
J Cancer Res Clin Oncol; 2014 Oct; 140(10):1671-80. PubMed ID: 24903965
[TBL] [Abstract][Full Text] [Related]
11. Sclerostin and Dickkopf-1 in renal osteodystrophy.
Cejka D; Herberth J; Branscum AJ; Fardo DW; Monier-Faugere MC; Diarra D; Haas M; Malluche HH
Clin J Am Soc Nephrol; 2011 Apr; 6(4):877-82. PubMed ID: 21164019
[TBL] [Abstract][Full Text] [Related]
12. Circulating Dickkopf-1 and sclerostin in patients with Paget's disease of bone.
Idolazzi L; Fassio A; Tripi G; Braga V; Viapiana O; Adami G; Rossini M; Gatti D
Clin Rheumatol; 2017 Apr; 36(4):925-928. PubMed ID: 28054306
[TBL] [Abstract][Full Text] [Related]
13. Bone Sclerostin and Dickkopf-related protein-1 are positively correlated with bone mineral density, bone microarchitecture, and bone strength in postmenopausal osteoporosis.
Peng J; Dong Z; Hui Z; Aifei W; Lianfu D; Youjia X
BMC Musculoskelet Disord; 2021 May; 22(1):480. PubMed ID: 34034718
[TBL] [Abstract][Full Text] [Related]
14. Effect of recent spinal cord injury on wnt signaling antagonists (sclerostin and dkk-1) and their relationship with bone loss. A 12-month prospective study.
Gifre L; Vidal J; Carrasco JL; Filella X; Ruiz-Gaspà S; Muxi A; Portell E; Monegal A; Guañabens N; Peris P
J Bone Miner Res; 2015 Jun; 30(6):1014-21. PubMed ID: 25484108
[TBL] [Abstract][Full Text] [Related]
15. Biomarkers and cytokines of bone turnover: extensive evaluation in a cohort of patients with ankylosing spondylitis.
Taylan A; Sari I; Akinci B; Bilge S; Kozaci D; Akar S; Colak A; Yalcin H; Gunay N; Akkoc N
BMC Musculoskelet Disord; 2012 Oct; 13():191. PubMed ID: 23025387
[TBL] [Abstract][Full Text] [Related]
16. Correlation of blood bone turnover biomarkers and Wnt signaling antagonists with AS, DISH, OPLL, and OYL.
Niu CC; Lin SS; Yuan LJ; Chen LH; Yang CY; Chung AN; Lu ML; Tsai TT; Lai PL; Chen WJ
BMC Musculoskelet Disord; 2017 Feb; 18(1):61. PubMed ID: 28153008
[TBL] [Abstract][Full Text] [Related]
17. Decreased Serum Wnt Antagonist Levels in Patients With Active Acromegaly.
Chen H; Huang H; Wang Y; Zhang Y; Liu M; Lou Y; Zhang Z; Zhu D; Li P
Endocr Pract; 2022 May; 28(5):515-520. PubMed ID: 35123069
[TBL] [Abstract][Full Text] [Related]
18. Wnt signaling pathway inhibitors, sclerostin and DKK-1, correlate with pain and bone pathology in patients with Gaucher disease.
Ivanova MM; Dao J; Kasaci N; Friedman A; Noll L; Goker-Alpan O
Front Endocrinol (Lausanne); 2022; 13():1029130. PubMed ID: 36506070
[TBL] [Abstract][Full Text] [Related]
19. Sclerostin and Pref-1 have differential effects on bone mineral density and strength parameters in adolescent athletes compared with non-athletes.
Fazeli PK; Ackerman KE; Pierce L; Guereca G; Bouxsein M; Misra M
Osteoporos Int; 2013 Sep; 24(9):2433-40. PubMed ID: 23579340
[TBL] [Abstract][Full Text] [Related]
20. Comparative effect of zoledronic acid versus denosumab on serum sclerostin and dickkopf-1 levels of naive postmenopausal women with low bone mass: a randomized, head-to-head clinical trial.
Anastasilakis AD; Polyzos SA; Gkiomisi A; Bisbinas I; Gerou S; Makras P
J Clin Endocrinol Metab; 2013 Aug; 98(8):3206-12. PubMed ID: 23788684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
